These studies provide the first biochemical characterization of the mechanisms through which MG adducts may function as not only biomarkers of DKD but also drivers of vascular disease, and identify a novel class of RAGE ligands and potential therapeutic modality to improve patient outcomes. This evidence concerns the gene AGER and diabetic kidney disease.